Phospholipase A2: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 99: | Line 99: | ||
**[[1kqu]], [[1kvo]] – hPLA2G2A+substrate analog<br /> | **[[1kqu]], [[1kvo]] – hPLA2G2A+substrate analog<br /> | ||
**[[3u8d]], [[3u8h]], [[3u8i]], [[4hmb]] - hPLA2G2A + inhibitor<br /> | **[[3u8d]], [[3u8h]], [[3u8i]], [[4hmb]] - hPLA2G2A + inhibitor<br /> | ||
**[[5g3n]] - hPLA2G2A (mutant) + inhibitor<br /> | |||
**[[3g8f]] – DrPLA2G2+polypeptide<br /> | **[[3g8f]] – DrPLA2G2+polypeptide<br /> | ||
**[[3mlm]] – PLA2G2 + myristic acid – ''Neuwiedi lancehead''<br /> | **[[3mlm]] – PLA2G2 + myristic acid – ''Neuwiedi lancehead''<br /> | ||
**[[4fga]], [[4gfy]], [[4gld]] – DrPLA2 + polypeptide | **[[4fga]], [[4gfy]], [[4gld]] – DrPLA2 + polypeptide | ||
*Human PLA2 group IVd | |||
**[[5ixc]] – hPLA2GIVD + fluorophosphonate derivative<br /> | |||
*Phospholipase A2 group V | *Phospholipase A2 group V | ||
| Line 109: | Line 114: | ||
*Human phospholipase A2 group X | *Human phospholipase A2 group X | ||
**[[1le6]], [[1le7]], [[4uy1]] – hPLA2G10 | **[[1le6]], [[1le7]], [[4uy1]], [[5g3m]] – hPLA2G10 | ||
*Human phospholipase A2 group XV | *Human phospholipase A2 group XV | ||
| Line 211: | Line 216: | ||
**[[3f98]] - hLP-PLA2 residues 47-429 + tabun<br /> | **[[3f98]] - hLP-PLA2 residues 47-429 + tabun<br /> | ||
**[[3f9c]] - hLP-PLA2 residues 47-429 + DFP<br /> | **[[3f9c]] - hLP-PLA2 residues 47-429 + DFP<br /> | ||
**[[5i8p]], [[5i9i]], [[5jad]], [[5jah]], [[5jal]], [[5jan]], [[5jao]], [[5jap]], [[5jar]], [[5jas]], [[5jat]], [[5jau]] - hLP-PLA2 residues 47-429 + inhibitor<br /> | **[[5i8p]], [[5i9i]], [[5jad]], [[5jah]], [[5jal]], [[5jan]], [[5jao]], [[5jap]], [[5jar]], [[5jas]], [[5jat]], [[5jau]], [[5lp1]], [[5lz2]], [[5lz8]], [[5lz9]] - hLP-PLA2 residues 47-429 + inhibitor<br /> | ||
**[[5lyy]], [[5lz4]], [[5lz5]], [[5lz7]] - hLP-PLA2 residues 47-429 (mutant) + inhibitor<br /> | |||
* Bothrops toxins | * Bothrops toxins | ||